Zanamivir

Drugs

Volumn 55, Issue 5, 1998, Pages 721-725

  Waghorn, S L ^a   Goa, K L ^a   Fleming, D M ^a   McKimm Breschkin, J L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; SIALIDASE INHIBITOR; VIRUS SIALIDASE; ZANAMIVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS;

EID: 0031901568     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855050-00015     Document Type: Article

References (24)

1. 1. LK Madren JC Shipman FG Hayden 1995 In vitro inhibitory effects of combinations of anti-influenza agents Antiviral Chem Chemother 6 109 13 1:CAS:528:DyaK2MXksVGjsb8%3D Madren LK, Shipman JC, Hayden FG. In vitro inhibitory effects of combinations of anti-influenza agents. Antiviral Chem Chemother 1995 Mar; 6: 109–13
2. 2. DRP Guay 1994 Amantadine and rimantadine prophylaxis of influenza A in nursing homes: a tolerability perspective Drugs Aging 5 8 19 7919641 10.2165/00002512-199405010-00002 1:STN:280:DyaK2M%2Fgtlegtg%3D%3D Guay DRP. Amantadine and rimantadine prophylaxis of influenza A in nursing homes: a tolerability perspective. Drugs Aging 1994 Jul; 5: 8–19
3. 3. A Whittington R Bethell 1995 Recent developments in the antiviral therapy of influenza Expert Opinion on Therapeutic Patents 5 793 803 10.1517/13543776.5.8.793 1:CAS:528:DyaK2MXnvFSjt7o%3D Whittington A, Bethell R. Recent developments in the antiviral therapy of influenza. Expert Opinion on Therapeutic Patents 1995 Aug; 5: 793–803
4. 4. JM Woods RC Bethell JA Coates 1993 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro Antimicrob Agents Chemother 37 1473 9 8363379 10.1128/AAC.37.7.1473 1:CAS:528:DyaK3sXlsFKjtr4%3D Woods JM, Bethell RC, Coates JA, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993 Jul; 37: 1473–9
5. 5. RC Bethell PW Smith 1997 Sialidase as a target for inhibitors of influenza virus replication Expert Opin Invest Drug 6 1501 9 10.1517/13543784.6.10.1501 1:CAS:528:DyaK2sXntVKkur8%3D Bethell RC, Smith PW. Sialidase as a target for inhibitors of influenza virus replication. Expert Opin Invest Drug 1997 Oct; 6: 1501–9
6. 6. FG Hayden BS Rollins LK Madren 1994 Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5-Ac2en in cell culture and in human respiratory epithelium Antiviral Res 25 123 31 7847874 10.1016/0166-3542(94)90101-5 1:CAS:528:DyaK2cXmslWgu70%3D Hayden FG, Rollins BS, Madren LK. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5-Ac2en in cell culture and in human respiratory epithelium. Antiviral Res 1994 Oct; 25: 123–31
7. 7. GP Thomas M Forsyth CR Penn 1994 Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid Antiviral Res 24 351 6 7993078 10.1016/0166-3542(94)90081-7 1:CAS:528:DyaK2cXmsVGiu7s%3D Thomas GP, Forsyth M, Penn CR, et al. Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid. Antiviral Res 1994 Aug; 24: 351–6
8. 8. DM Ryan J Ticehurst MH Dempsey 1994 Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3,-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase) Antimicrob Agents Chemother 38 2270 5 7840556 10.1128/AAC.38.10.2270 1:CAS:528:DyaK2cXmsVGht7o%3D Ryan DM, Ticehurst J, Dempsey MH, et al. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3,-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother 1994 Oct; 38: 2270–5
9. 9. DM Ryan J Ticehurst MH Dempsey 1995 GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets Antimicrob Agents Chemother 39 2583 4 8585752 10.1128/AAC.39.11.2583 1:CAS:528:DyaK2MXptFylsbY%3D Ryan DM, Ticehurst J, Dempsey MH. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother 1995 Nov; 39: 2583–4
10. 10. JL McKimm-Breschkin TJ Blick A Sahasrabudhe 1996 Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-neu5Ac2en and 4-guanidino-neu5Ac2en Antimicrob Agents Chemother 40 40 6 8787876 1:CAS:528:DyaK28XhvFKqtQ%3D%3D McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, et al. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-neu5Ac2en and 4-guanidino-neu5Ac2en. Antimicrob Agents Chemother 1996 Jan; 40: 40–6
11. 11. JM Colacino WG Laver GM Air 1997 Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture J Infect Dis 176 1 S66 8 9240698 10.1086/514179 1:CAS:528:DyaK2sXlsVKkt78%3D Colacino JM, Laver WG, Air GM. Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture. J Infect Dis 1997 Aug; 176 Suppl. 1: S66–8
12. 12. LV Gubareva MJ Robinson RC Bethell 1997 Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en J Virol 71 3385 90 9094607 1:CAS:528:DyaK2sXisFWgtL0%3D Gubareva LV, Robinson MJ, Bethell RC, et al. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997 May; 71: 3385–90
13. 13. Barnett J, Dempsey M, Tisdale M, et al. Susceptibility monitoring of influenza virus clinical isolates to the neuraminidase inhibitor zanamivir ((GG167) during phase II clinical efficacy trials[abstract no. H-93]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 280
14. 14. Efthymiopoulos C, Barrington P, Patel J, et al. Pharmacokinetics of the neuraminidase inhibitor 4-guanidino Neu5Ac2en (GG167) following intravenous, intranasal and inhaled administration in man [abstract]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4–7; Orlando (FL), 265
15. 15. Newman SP, Brown J, Pickford M, et al. Deposition pattern in the respiratory tract of the neuraminidase inhibitor zanamivir; a gamma scintigraphic study [abstract no. H-134]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 237
16. 16. Hussey E, Hayden F, Grosse C, et al. Serum and urine GG167 concentrations in healthy subjects inoculated experimentally with influenza A virus [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco, 25
17. 17. MC Peterson KR Sweeney PH Hsyu 1996 Renal disposition and drug screening of GR121167 (GG167) in the isolated perfused rat kidney [abstract] Pharm Res 13 448 Peterson MC, Sweeney KR, Hsyu PH. Renal disposition and drug screening of GR121167 (GG167) in the isolated perfused rat kidney [abstract]. Pharm Res 1996 Sep; 13 Suppl.: 448
18. 18. Schilling M, Povinelli L, Krause P, et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza A outbreaks [abstract no. H-92]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 230
19. 19. FG Hayden JJ Treanor RF Betts 1996 Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza JAMA 275 295 9 8544269 10.1001/jama.1996.03530280047035 1:CAS:528:DyaK28Xhtl2rsbc%3D Hayden FG, Treanor JJ, Betts RF, et al. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996 Jan 24–31; 275: 295–9
20. 20. FG Hayden ADME Osterhaus JJ Treanor 1997 Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections N Engl JMed 337 874 80 10.1056/NEJM199709253371302 1:CAS:528:DyaK2sXmtlylur8%3D Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl JMed 1997 Sep 25; 337: 874–80
21. 21. Aoki F, Fleming D, Lacey L, et al. Impact of treatment of influenza with zanamivir on patients’ health status, sleep quality, productivity and healthcare use [abstract no. N-15]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 384
22. 22. WJ Rodriguez CB Hall R Welliver 1994 et al Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J Pediatr 125 129 135 1:STN:280:DyaK2c3ptlWjtg%3D%3D Rodriguez WJ, Hall CB, Welliver R. et al. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J Pediatr 1994; 125: 129–135
23. 23. Cass LMR. Efthymiopoulos C, Bye A. An overview of the pharmacokinetics of the neuraminidase inhibitor GG167 [abstract]. Options for the control of influenza III. 1996 May; Cairns
24. 24. Data on file. Glazo Wellcome